Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bd3250b01afab1350424b4533aa097b1d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bd3250b01afab1350424b4533aa097b1d NCIT_P378 "NCI" @default.
- Bd3250b01afab1350424b4533aa097b1d type Axiom @default.
- Bd3250b01afab1350424b4533aa097b1d annotatedProperty IAO_0000115 @default.
- Bd3250b01afab1350424b4533aa097b1d annotatedSource NCIT_C186367 @default.
- Bd3250b01afab1350424b4533aa097b1d annotatedTarget "A preparation of genetically modified autologous T-lymphocytes that are transduced with a single lentiviral vector (LVV) to express chimeric antigen receptors (CARs) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 20 (CD20) and the B-cell antigen receptor complex-associated protein alpha chain (CD79a), and transfected with an mRNA encoding the Casitas B-lineage lymphoma proto-oncogene-b (CBLB)-targeting megaTAL enzyme to edit the CBLB gene, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD20/CD79a CAR-T cells bbT369 target and bind to CD20- and CD79a-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD20 and CD79a are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD20 and CD79a may prevent tumor cell antigen escape and relapse, and may increase anti-tumor activity. The removal of CBLB, an E3 ubiquitin ligase and a negative regulator of T-cell function, will increase T-cell expansion and activation." @default.